NEW YORK, Dec. 14, 2023 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Entrada Therapeutics, Inc. ("Entrada" or the "Company") (NASDAQ:TRDA). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.
The investigation concerns whether Entrada and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.
[Click here for information about joining the class action]
After the market closed on December 19, 2022, Entrada issued a press release announcing that the U.S. Food and Drug Administration ...